The number of companies choosing to stay private for longer continues to grow and asset allocators are supporting this trend with global private markets AUM now at circa USD 24 trillion. And the US is leading the way in this trend. Private growth fundraising continues to rise in the US whilst it may be slowing in Europe and other parts of the world.
"FlowwCapital is therefore excited to share more about the first US opportunities from key sectors, made available to US and non-US investor through different regulatory journeys."
Built to be hard to copy
Bringing US private companies to a breadth of investors isn't a listing-page problem. It's three things that rarely coexist: the regulatory permissions, the cross-border infrastructure to settle and service securities, and the compliance discipline once live. Most platforms have built one aspect. Floww built all three.
Here's the practical effect. Until now, an investor outside the US wanting exposure to US private company growth financing had two options: go direct and absorb the cross-border regulatory risk themselves, or go through a platform that wasn't built to carry that risk on their behalf. We are closing that gap — the access exists, it's compliant end to end, and it's live.
What's live today
Our first three US deals are companies operating in the AI and biotech space. They're open to our investor community today through our US and UK channels.
Eos SENOLYTIX, Inc. A biotechnology company developing therapeutics that target the biology of aging itself, not just its symptoms. Its lead candidate, PTC-2105, is a mitochondrial-targeted molecule built to recharge aging cells while clearing the senescent "zombie" cells behind age-related decline, sitting on a platform backed by roughly eight years of research. Its first target is sarcopenia and sarcopenic obesity: the age-related muscle loss that today's GLP-1 weight-loss drugs cause but don't treat, a large and growing population with no approved therapy.
Oral Biolife. A US oral health biotech company developing a hydrogel platform that treats periodontal (gum) disease by regenerating lost bone and tissue, using mechanical stress to trigger the body's own repair signals, without surgery or grafting.
New Sapience. A Maryland-based AI company built around a different bet on Artificial Intelligence: instead of scaling data and compute, it teaches machines to reason from human-derived knowledge, building what it calls an "inner world model".
Find out more here:
Your support
If you are already in our network, log in and find out more about the companies. If you are interested in US dealflow and haven't joined yet, register your interest and gain access to the latest deals on confirmation of your investor status.
This article references Eos SENOLYTIX, Inc.; Oral Biolife Inc.; and New Sapience Inc. for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any security. Eligibility requirements apply and differ by jurisdiction – please select the link that applies to you.
This communication is issued and approved by Floww Markets Limited (FRN 980098), authorised and regulated by the Financial Conduct Authority. Investments of this type are Non-Readily Realisable Securities, high-risk, illiquid and not readily transferable securities. You could lose all the money you invest and are unlikely to be protected if something goes wrong. Take 2 minutes to learn more before investing.
These offerings are being made in reliance on an exemption from the registration requirements under the Securities Act of 1933, as amended (the "Securities Act") set forth in section 4(a)(2) thereof and Rule 506(c) of regulation D promulgated thereunder ("Rule 506") and certain state securities laws as an offer and sale of securities not involving a public offering. No assurance can be given that a public market will develop for the common stock. The securities may not be transferred without satisfaction of certain conditions, including registration or the availability of an exemption under the securities act and the securities laws of certain states. Prospective investors should assume that they may have to bear the economic risk of an investment in the securities for an indefinite period of time. Rule 506 sets forth certain restrictions as to the number and nature of purchasers of securities offered pursuant thereto. We have elected to sell securities only to accredited investors, as such term is defined in Rule 501(a) of regulation D ("accredited investors"). Each prospective investor will be required to make representations as to the basis upon which it qualifies as an accredited investor. Prospective investors should rely only on the information contained in the definitive offering documents and should make their own independent investment decision based on their own review and that of their legal, tax, financial, and other advisors.